Novartis acquires Excellergy to bolster allergy portfolio
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
It promises fewer injections for vision loss patients
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
Subscribe To Our Newsletter & Stay Updated